Navigation Links
Rice chemists cram 2 million nanorods into single cancer cell
Date:11/16/2011

Rice University chemists have found a way to load more than 2 million tiny gold particles called nanorods into a single cancer cell. The breakthrough could speed development of cancer treatments that would use nanorods like tiny heating elements to cook tumors from the inside.

The research appears online this week in the chemical journal Angewandte Chemie International Edition.

"The breast cancer cells that we studied were so laden with gold nanorods that their masses increased by an average of about 13 percent," said study leader Eugene Zubarev, associate professor of chemistry at Rice. "Remarkably, the cells continued to function normally, even with all of this gold inside them."

Though the ultimate goal is to kill cancer, Zubarev said the strategy is to deliver nontoxic particles that become deadly only when they are activated by a laser. The nanorods, which are about the size of a small virus, can harvest and convert otherwise harmless light into heat. But because each nanorod radiates miniscule heat, many are needed to kill a cell.

"Ideally, you'd like to use a low-power laser to minimize the risks to healthy tissue, and the more particles you can load inside the cell, the lower you can set the power level and irradiation time," said Zubarev, an investigator at Rice's BioScience Research Collaborative (BRC).

Unfortunately, scientists who study gold nanorods have found it difficult to load large numbers of particles into living cells. For starters, nanorods are pure gold, which means they won't dissolve in solution unless they are combined with some kind of polymer or surfactant. The most commonly used of these is cetyltrimethylammonium bromide, or CTAB, a soapy chemical often used in hair conditioner.

CTAB is a key ingredient in the production of nanorods, so scientists have often relied upon it to make nanorods soluble in water. CTAB does this job by coating the surface of the nanorods in much the same way that soap envelopes and dissolves droplets of grease in dishwater. CTAB-encased nanorods also have a positive charge on their surfaces, which encourages cells to ingest them. Unfortunately, CTAB is also toxic, which makes it problematic for biomedical applications.

In the new research, Zubarev, Rice graduate student Leonid Vigderman and former graduate student Pramit Manna, now at Applied Materials Inc., describe a method to completely replace CTAB with a closely related molecule called MTAB that has two additional atoms attached at one end.

The additional atoms -- one sulfur and one hydrogen -- allow MTAB to form a permanent chemical bond with gold nanorods. In contrast, CTAB binds more weakly to nanorods and has a tendency to leak into surrounding media from time to time, which is believed to be the underlying cause of CTAB-encased nanorod toxicity.

It took Zubarev, Vigderman and Manna several years to identify the optimal strategy to synthesize MTAB and substitute it for CTAB on the surface of the nanorods. In addition, they developed a purification process that can completely remove all traces of CTAB from a solution of nanorods.


'/>"/>

Contact: David Ruth
druth@rice.edu
713-348-6327
Rice University
Source:Eurekalert

Related medicine news :

1. UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug
2. Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme
3. MIT chemists engineer plants to produce new drugs
4. Flu Hits 90 Million Children Under 5 Each Year
5. Getting on your nerves: $1.4 million NIH grant to study the regeneration of nerves
6. Scripps Research scientist receives $1 million research grant from Novo Nordisk
7. Scott & White Cancer Research Institute receives $3.5 million grant
8. Earthquakes Put Millions of Lives, Major Cities at Risk
9. Penn collaborates on $8 million Barretts esophagus research network
10. NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria
11. BUSM researcher awarded 2 NIH grants totaling over $11 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide ... we as a society can control and change. , As nearly 795,000 Americans suffering ... seconds within the United States. Plus, with an estimated 129,000 of these people dying ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
Breaking Medicine Technology: